Jersey's Medical Cannabis Prescriptions Jumped 35% in One Year

The island dispensed 72,065 medical cannabis products in 2025, and the growth figure needs careful reading before anyone draws conclusions from it.

By Cannible Editorial

2026-09-03

Jersey dispensed 72,065 medical cannabis products in 2025, up from 53,477 the year before, a 35% increase in a single year. The figures come from a Freedom of Information request reported by the Jersey Times and covered by the International Cannabis Business Conference. The number is significant, and it is also incomplete on its own: it counts products, not patients, and utilisation is not evidence that cannabis treated anything. If you are trying to understand where Jersey sits, read the growth figure alongside the fact that non-medical reform on the island is currently stalled.

Here is the short version before the detail.

• The headline figure: 72,065 medical cannabis products dispensed in Jersey in 2025, up from 53,477 in 2024.
• The longer arc: dispensed products have more than tripled since 2022, when the total was 23,639.
• The important caveat: prescriptions are not patients. Government figures put the patient count at roughly 4,000 individuals in 2024, served by 20 prescribers.
• The political gap: medical prescribing keeps expanding while a proposition on personal cannabis use was withdrawn in January 2026 over wording.
• The regulatory response: Health Minister Tom Binet confirmed in 2026 that formal legal controls on prescribing practice were being developed, with new regulations expected by year-end.

This article is general information, not medical or legal advice. Prescribing rules and cannabis law in Jersey are changing. Confirm current requirements with a licensed prescriber, a pharmacist, or the relevant Jersey authority before acting on anything here.

International Cannabis Business Conference: Medical Cannabis Prescriptions in Jersey Increased by 35% — The news hook, reporting figures attributed to a Freedom of Information request and Jersey Times reporting.

What Jersey's 35% increase actually measures

The 35% figure describes dispensed products, not people, not conditions treated, and not outcomes. In 2025, pharmacies in Jersey dispensed 72,065 medical cannabis products. In 2024, the equivalent figure was 53,477. The difference between those two totals is the growth rate everyone is quoting.

That distinction matters more than it might appear. A single patient can receive multiple prescriptions across a year, so a rising product count can reflect more patients, more frequent repeat prescribing, larger prescribed quantities, or any combination of the three. The published figure does not separate those causes.

The figures reach the public through a chain of attribution rather than a direct dataset. They originate in a Freedom of Information response, were reported by the Jersey Times, and were then covered by the International Cannabis Business Conference. Treat the reporting as reliable within that chain, and treat the underlying FOI response as the primary document if you need to verify anything specific.

Growth inside an established framework, not a new one

Jersey has allowed cannabis-based medical prescribing since 2019. That matters for interpretation. This is not the early spike you see when a jurisdiction opens a brand new pathway and a backlog of interested patients arrives at once. It is continued acceleration inside a framework that has been running for years.

The longer arc makes the point clearly. Dispensed products have more than tripled since 2022, climbing from 23,639 in that year to 72,065 in 2025.

The pace also picked up within 2025 itself. Pharmacies dispensed 33,296 items in the first half of the year and 38,769 in the second half. Demand was stronger as the year closed than when it opened, which suggests the trend was still building rather than flattening out at the point the data ends.

What the numbers do not say

Two distinctions do most of the work here, and skipping either one produces a misleading reading of the data.

First, prescriptions are not patients. The 72,065 figure counts prescribed products. One patient typically receives multiple prescriptions across a year. Government figures put the actual patient count at roughly 4,000 individuals served by 20 prescribers in 2024. Officials noted that even that figure is an approximation, given data limitations.

Second, prescription growth is not clinical proof. Higher utilisation means more products moved through the system. It does not show that cannabis successfully treated any specific condition. These figures are not evidence of efficacy, and nothing in the reporting claims they are.

On the evidence grading: what we have here is administrative dispensing data, which is strong for describing volume and weak for describing outcomes. It tells you what was dispensed. It tells you nothing about whether patients improved, whether prescribing was clinically appropriate, or how the patient population is distributed across conditions.

Two tracks moving at two different speeds

Medical access and broader legalisation are on separate political tracks in Jersey, and they are not moving at the same pace.

As prescribing surged, a proposition titled "Future approach to personal cannabis use in Jersey" was lodged in December 2025. It set out three options: decriminalisation, legalisation, or a Swiss-style regulated trial. Lawmakers withdrew it in January 2026 over wording issues with the first option.

That leaves Jersey in an unusual position. Its medical system serves a meaningful share of the population, while non-medical reform sits at the drafting stage, unresolved.

Here is the split, stated plainly.

• Medical track: operating since 2019, dispensing 72,065 products in 2025, roughly 4,000 patients and 20 prescribers as of 2024.
• Non-medical track: a three-option proposition lodged in December 2025 and withdrawn in January 2026 over wording.
• Regulatory track: formal legal controls on prescribing practice under development in 2026, with regulations expected by year-end.

Why regulators are now moving on prescribing

Growth at this rate attracts oversight. Health Minister Tom Binet confirmed in 2026 that officers were developing formal legal controls on prescribing practice, with new regulations expected by the end of the year.

Read that as a structural response rather than a restrictive one. The government's position, as reported, is that the growth rate needs structure behind it. When 6% of a working population holds a prescription and the product count has tripled in three years, the practical questions become who is prescribing, on what basis, and with what record-keeping.

For patients, the near-term implication is that the rules governing how they obtain a prescription may look different once the new regulations land. Nothing in the reporting indicates what those controls will contain, so treat the specifics as unknown until the regulations are published.

Why this pattern matters beyond Jersey

Jersey is a small island, which makes it a useful lens. It functions as a compressed case study in how cannabis normalises through medicine before it normalises anywhere else.

The pattern reaches beyond the Channel Islands. Private medical cannabis prescriptions in the UK more than doubled between 2023 and 2024, rising from around 283,000 to 659,000, with an estimated 80,000 to 100,000 active patients by 2025. Jersey's trajectory fits a wider British shift rather than standing apart from it.

The core insight is that medicine and markets liberalise on separate timelines. A jurisdiction can build robust medical access, serve thousands of patients, and still hold off on adult-use reform for years. Jersey is a clear example of exactly that.

Doctors, pharmacists and patients are normalising cannabis inside clinical practice every day. Legislatures move when they are ready. In Jersey, they are not ready yet.

How to read this story without overreading it

Jersey's 35% jump is real, documented within its attribution limits, and still accelerating at the point the data ends. The honest reading is narrower than the headline, and it is still a meaningful story.

Three rules keep you accurate.

• Count products as products. 72,065 is a dispensing figure, not a headcount.
• Treat patient numbers as approximations. Officials said so themselves about the roughly 4,000 figure for 2024.
• Do not read utilisation as clinical proof. Volume data cannot speak to outcomes.

Cannabis is becoming routine inside Jersey's medical system, one prescription at a time, while the broader legal question waits for lawmakers to agree on wording. The gap between clinical reality and political readiness is where the most consequential cannabis policy stories are unfolding right now.

Frequently asked questions

Key takeaways

• 35% year-on-year growth: 72,065 products dispensed in 2025 against 53,477 in 2024.
• Tripled since 2022: the total has climbed from 23,639 in 2022 to 72,065 in 2025, and accelerated within 2025 itself, from 33,296 items in the first half to 38,769 in the second.
• Roughly 4,000 patients, not 72,065: government figures for 2024 put the patient count at about 4,000, served by 20 prescribers, and describe that number as an approximation.
• Unusual penetration: a 2024 audit found roughly 6% of Jersey's working population holds a medical cannabis prescription, against about 0.05% in England.
• Reform is stalled, oversight is not: the personal-use proposition was withdrawn in January 2026, while formal prescribing controls were expected by the end of 2026.
• Utilisation is not efficacy: none of these figures speak to clinical outcomes.

The Cannible Newsroom's take

What we would tell a friend reading this story is to separate the two things that keep getting welded together. The dispensing data is genuinely striking. A figure that triples in three years inside an established framework is not noise. But the number being quoted counts boxes leaving pharmacies, and the patient figure behind it, around 4,000, is both much smaller and explicitly described by officials as approximate. Anyone using 72,065 as a proxy for patient numbers is misreading it.

What concerns us is the evidence gap. Jersey has one of the highest per-capita medical cannabis prescription rates in the region, roughly 6% of the working population against about 0.05% in England, and there is no outcome data in this reporting to sit alongside it. That is not an argument that the prescribing is inappropriate. It is an argument that nobody can currently say much about whether it is working, and that is an uncomfortable place for a health system to be when volumes are climbing this fast.

The nuance is in the political split. It is tempting to treat medical growth as a leading indicator of adult-use reform, and Jersey shows why that is unreliable. Medical access expanded through 2025 while the personal-use proposition was withdrawn in January 2026 over the wording of a single option. Clinical normalisation and legislative readiness are not the same variable, and they can move in opposite directions for years.

We will update this article as Jersey's prescribing regulations are published, as new dispensing figures are released, and as the personal-use question returns to the legislature.

Sources and further reading

• International Cannabis Business Conference: Medical Cannabis Prescriptions in Jersey Increased by 35%, reporting figures attributed to a Freedom of Information request and Jersey Times reporting.
• Jersey Evening Post: Medicinal cannabis controls set to come into force by end of year, on the longer growth arc since 2022 and the expected regulations.
• Bailiwick Express: Medicinal cannabis prescriptions surge to more than 72,000 in a year, on the half-year split and the approximate patient and prescriber counts.
• Cannabis.org.je: Jersey Elections 2026, on the withdrawal of the personal cannabis use proposition in January 2026.
• The Jersey Times, as the originating outlet for the Freedom of Information figures, cited in the reporting above.

If you hold or are seeking a medical cannabis prescription in Jersey, confirm current rules with a licensed prescriber, your pharmacist, or the relevant Jersey health authority rather than relying on news coverage.

Where to go next

If you are working out how legal access actually functions where you live, start with the practical guides rather than the policy debate. Our buyer's guide to choosing a dispensary covers what to check before you hand over money, and the dispensary directory lets you see what is licensed and operating near you. If you want to understand what is actually being prescribed and sold rather than how it is regulated, the strain library is the better starting point.